Publication of prospectus with respect to Aerocrine´s new

Publication of prospectus with respect to Aerocrine´s new share issue 2008

The board of directors of Aerocrine AB has prepared a prospectus with respect to
a share issue with preferential rights for the company´s shareholders. The
prospectus is available on www.aerocrine.com or www.avanza.se (ongoing
projects).

The prospectus is also available free of charge from Aerocrine AB,
Sundbybergsvägen 9, Box 1024, SE-171 73 Solna, Sweden, as well as from Avanza
Bank AB, Klarabergsgatan 60, Box 1399, SE-111 93 Stockholm, Sweden. Shareholders
who are directly registered as holders of the Aerocrine share as at  November 13
will receive the prospectus by mail.

Solna November 12 2008
Aerocrine AB (publ)

For further information contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82
---------------------------

This press release may not be announced, published or disseminated, directly or
indirectly, in the United States of America, Canada, Australia, Hong Kong, Japan
or in any other country where such measure wholly or partly is subject to
restrictions by law.

The information in this press release may not be forwarded, reproduced or shown
in way that is in conflict with such restrictions. Failure to comply with this
instruction may constitute a crime according the United States Securities Act of
1933 ("Securities Act") or applicable laws in other jurisdictions.

Nothing in this press release shall be deemed to constitute and offer to invest,
subscribe or otherwise deal with shares, subscription right or other securities
of Aerocrine.

Neither the subscription right, nor the paid and subscribed shares or the new
shares will be registered according the Securities Act or any provincial law in
Canada and may not be transferred or offered for sale in the USA or Canada, or
to a person domiciled in such state or for such persons account other in
excepted cases, where registration is not required according the Securities act
or any provincial law in Canada.
---------------------------


About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in the technology to monitor and manage airway inflammation, Aerocrine
markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine discloses the information provided herein pursuant to the Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 12:00 a.m. on November the 12th 2008.